U.S. Pharma Stock News

Wondering if Dell Technologies at around US$151.62 is still fairly priced, starting to look expensive, or offering value? This article is designed to help you frame that question clearly. The stock has seen strong momentum recently, with returns of 3.5% over 7 days, 22.1% over 30 days, 18.6% year to date, 61.4% over 1 year and 332.1% over 3 years. That naturally raises questions about what is already priced in. Recent coverage has focused on Dell as a key name in large scale computing and...

If you are wondering whether Blue Owl Capital's share price now reflects good value or just fresh risks, you are not alone. This article is here to unpack that question clearly. Over the short term the stock has seen sharp moves, with a 7 day return of an 11.5% decline, a 30 day return of a 30.6% decline and a year to date return of a 42.8% decline, while the 1 year return sits at a 51.8% decline compared to a 6.4% gain over 5 years and a 1.9% decline over 3 years. Recent headlines around...

If you are wondering whether Mohawk Industries at around US$102.55 is a potential bargain or a value trap, you are not alone. The stock has seen a 24.0% decline over the last 30 days and is down 10.3% over the past year, even though the 3 year return sits at 8.7%. Recent headlines have focused on Mohawk Industries' position in the flooring and broader consumer durables market, including how it is responding to shifts in housing activity and renovation demand. This context has kept attention...

Recent share performance and business snapshot Under Armour (UAA) has had a mixed run recently, with the stock down over the past month but positive over the past 3 months. This may prompt investors to reassess the story. The company generated revenue of about US$4.98b and reported a net loss of roughly US$519.71 million, while long term total returns over 3 and 5 years have been negative. This highlights ongoing turnaround questions. See our latest analysis for Under Armour. At a share price...

Event context and recent share performance Hanover Insurance Group (THG) has been on investors’ radar after recent share swings, including a roughly 6% decline over the past 3 months and a small gain over the past month. See our latest analysis for Hanover Insurance Group. At a share price of US$173.39, Hanover Insurance Group’s recent 1 day and 7 day share price declines sit against a modest 1 year total shareholder return of 4.5% and a strong 3 year total shareholder return of 53.4%. This...

Butler National (BUKS) has reported Q3 2026 revenue of US$26.9 million and basic EPS of US$0.10, set against trailing twelve month revenue of US$91.9 million and EPS of US$0.30 that came with 44.1% earnings growth and a 21.4% net margin over the past year. The company has seen quarterly revenue move from US$21.2 million in Q3 2025 to US$26.9 million in Q3 2026 and basic EPS from US$0.05 to US$0.10 across the same periods, with trailing net income reaching US$19.7 million, which positions the...

In recent weeks, Vital Farms reported weaker-than-expected quarterly earnings, prompting multiple law firms to launch securities investigations while the stock touched a new 52-week low and sector-wide pressures weighed on sentiment. Amid these legal probes and analyst concerns, Director Karl Khoury’s purchase of 5,000 additional shares stands out as a contrasting insider confidence signal. We’ll now examine how the earnings disappointment and resulting legal investigations might reshape...

In early March 2026, Tenaya Therapeutics reported a narrower full-year 2025 net loss of US$90.6 million and highlighted new preclinical data for TN-301 in Duchenne muscular dystrophy alongside a research collaboration with Alnylam Pharmaceuticals on up to 15 cardiovascular gene targets that could yield as much as US$1.13 billion in milestones. Together, these updates underscore how Tenaya is pairing emerging HDAC6 science in DMD and heart failure with a genetically guided partnership model...

Earlier this month, Universal Technical Institute reported that it beat its fiscal 2025 operational targets with double‑digit revenue growth while a director, Shannon Lei Okinaka, sold 10,000 shares, about one‑third of her direct holdings, for roughly US$347,414 in an open‑market transaction on March 6, 2026. These developments come as the company is funding an ambitious multi‑year campus expansion that is compressing near‑term profits but is intended to support higher long‑term revenue and...

REX American Resources recently saw its market value reach about US$1.30 billion as its shares moved to fresh highs, ahead of reporting fiscal fourth-quarter and full-year 2025 results on 26 March 2026. This momentum comes even after earlier revenue and earnings declines, as higher oil prices renew attention on REX’s ethanol business as an alternative fuel option. Next, we’ll examine how this oil price-driven momentum in REX’s ethanol operations could influence the company’s existing...

If you are wondering whether Establishment Labs Holdings at around US$63.35 is still offering value or has already run too far, this article is designed to walk you through that question step by step. The share price has seen a 71.0% return over the past year, even though the stock is down 10.0% over the last week, 12.9% over the last month, and 8.0% year to date. This can change how investors think about both its growth potential and risk. Recent news around Establishment Labs has mainly...

Capricor Therapeutics (CAPR) has just posted its FY 2025 first half results with total revenue of US$0 million and a basic EPS loss of US$1.10, while trailing twelve month revenue sits at US$13.39 million with a basic EPS loss of US$1.66. Over recent periods, the company has reported revenue of US$8.88 million and US$13.39 million across the two halves of FY 2024, alongside basic EPS losses of US$0.66 and US$0.51. This provides context for how current margins remain under pressure. With...

Institutional stake cut puts Applied Industrial Technologies in focus Victory Capital Management Inc. recently cut its stake in Applied Industrial Technologies (AIT) by 45.2% in the third quarter, reducing its position to 86,330 shares from 157,638. This move has drawn fresh attention to the stock. See our latest analysis for Applied Industrial Technologies. At a share price of US$255.65, Applied Industrial Technologies has seen a 1 month share price return of 11.94% decline and a year to...

Why SELLAS Life Sciences Group (SLS) Is Back On Traders’ Screens SELLAS Life Sciences Group (SLS) has drawn fresh attention after a sharp move in its share price, with the stock showing a strong gain over the past 3 months and a solid performance over the past month. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of US$5.37, SELLAS Life Sciences Group has paired a 46.32% 30 day share price return with a very large 1 year total shareholder return, hinting that...

Why Hess Midstream (HESM) is back on investor radars Hess Midstream (HESM) is drawing fresh attention after its board authorized a new buyback plan, and the partnership signed a repurchase agreement with JPMorgan to retire up to US$42 million of Class A shares. See our latest analysis for Hess Midstream. At a share price of US$38.99, Hess Midstream has recorded a 7.12% 1 month share price return and 11.94% 3 month share price return. Its 5 year total shareholder return of 166.77% contrasts...

Constellium (NYSE:CSTM) has announced a new share repurchase program of up to $300 million, authorized through the end of 2028. The new program replaces the previous buyback authorization. Constellium intends to use some repurchased shares to settle employee equity obligations, aiming to limit future dilution for shareholders. Constellium, trading at $24.61, has laid out a fresh $300 million buyback plan that directly addresses dilution, which many shareholders watch closely. The stock has...

Orchestra BioMed Holdings (OBIO) just posted a sharp step up in activity for FY 2025, with fourth quarter revenue at US$30.9 million and basic EPS of US$0.10, compared with a full year where trailing twelve month revenue sat at US$33.5 million and EPS on that basis was a loss of US$1.11. The company has seen revenue move from quarterly levels below US$1 million through most of the year to the current US$30.9 million print, while quarterly basic EPS shifted from losses between US$0.49 and...

If you have been wondering whether Universal Display's current share price reflects its true worth, you are not alone. This article aims to unpack that question clearly. The stock last closed at US$94.07, and returns of a 3.1% decline over 7 days, a 28.8% decline over 30 days, and a 22.8% decline year to date, as well as a 36.6% decline over 1 year, a 31.9% decline over 3 years, and a 57.2% decline over 5 years, may have reset expectations and risk perceptions for many investors. Recent news...

International Flavors & Fragrances (IFF) is back in focus after fragrance and chemicals peers came under pressure from higher petroleum input costs and concern that pricier fuel could weigh on consumer demand for fragrance products. See our latest analysis for International Flavors & Fragrances. Despite recent headlines around higher petroleum costs and consumer demand risks, International Flavors & Fragrances' 90 day share price return of 10.04% contrasts with a 1 year total shareholder...

Northwest Bancshares (NasdaqGS:NWBI) President and CEO Louis J. Torchio recently acquired additional company shares, increasing his personal stake. The insider purchase took place around the time the bank reported strong fourth quarter financial results. The quarter featured earnings and revenue that were ahead of prior expectations, alongside the insider buying activity. Northwest Bancshares is a regional financial institution focused on community banking services, including deposits,...

USA Compression Partners (NYSE:USAC) has agreed to acquire J-W Power, expanding its contract compression fleet and specialty manufacturing capabilities. The deal is positioned around asset repricing opportunities and deeper participation in compression equipment manufacturing. Management is framing the combination as a way to serve rising demand tied to LNG infrastructure and power needs from AI focused data centers. Industry capacity remains tight, with longer lead times for new compression...

AC Immune (NasdaqGM:ACIU) just posted third quarter FY 2025 revenue of CHF 0.9 million and a basic EPS loss of CHF 0.16, with quarterly net income excluding extra items at a loss of CHF 15.9 million. Over recent periods the company has seen revenue move between CHF 0.7 million and CHF 25.5 million per quarter, while EPS has ranged from a loss of around CHF 0.23 per share to a modest profit of CHF 0.06 per share, which underscores how sensitive results can be to revenue timing. For investors,...

In early March 2026, Saia, Inc. reported January and February less-than-truckload operating metrics showing modest shipment softness, heavier tonnage declines, and lower weight per shipment compared with the same months in 2025, alongside mid-single-digit contractual renewal increases. Soon after, an analyst highlighted that this weaker freight activity and a worsening operating ratio were pressuring Saia’s operational efficiency at the same time the company is pursuing network...

Here Group (NasdaqGM:HERE) has just reported Q2 2026 results that mark a sharp reset in the top line, with revenue at C¥127.1 million and a basic EPS loss of C¥0.49, while the trailing 12 month figures still reflect a net profit margin of 12.3%. Over recent quarters the company has seen revenue move from C¥1,000.1 million in Q4 2024 to C¥810.4 million in Q1 2025, then to C¥726.6 million in Q2 2025, C¥570.7 million in Q3 2025 and C¥617.8 million in Q4 2025. Over the same period, basic EPS...